vs
Side-by-side financial comparison of Amneal Pharmaceuticals, Inc. (AMRX) and WARRIOR MET COAL, INC. (HCC). Click either name above to swap in a different company.
Amneal Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($722.5M vs $458.6M, roughly 1.6× WARRIOR MET COAL, INC.). WARRIOR MET COAL, INC. runs the higher net margin — 15.8% vs 10.8%, a 5.0% gap on every dollar of revenue. On growth, WARRIOR MET COAL, INC. posted the faster year-over-year revenue change (52.1% vs 3.9%). Over the past eight quarters, WARRIOR MET COAL, INC.'s revenue compounded faster (7.5% CAGR vs 1.5%).
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.
Warrior Met Coal, Inc. (ticker HCC) is a U.S.-headquartered mining enterprise that produces and distributes high-grade metallurgical coal, a key raw material for steel production. It serves steel manufacturers and industrial clients across core markets including North America, Europe, and Asia.
AMRX vs HCC — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $722.5M | $458.6M |
| Net Profit | $78.0M | $72.3M |
| Gross Margin | 44.3% | 36.7% |
| Operating Margin | — | 17.3% |
| Net Margin | 10.8% | 15.8% |
| Revenue YoY | 3.9% | 52.1% |
| Net Profit YoY | 217.0% | — |
| EPS (diluted) | $0.19 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $722.5M | $458.6M | ||
| Q4 25 | $814.3M | $384.0M | ||
| Q3 25 | $784.5M | $328.6M | ||
| Q2 25 | $724.5M | $297.5M | ||
| Q1 25 | $695.4M | $299.9M | ||
| Q4 24 | $730.5M | $297.5M | ||
| Q3 24 | $702.5M | $327.7M | ||
| Q2 24 | $701.8M | $396.5M |
| Q1 26 | $78.0M | $72.3M | ||
| Q4 25 | $35.1M | $23.0M | ||
| Q3 25 | $2.4M | $36.6M | ||
| Q2 25 | $22.4M | $5.6M | ||
| Q1 25 | $12.2M | $-8.2M | ||
| Q4 24 | $-31.1M | $1.1M | ||
| Q3 24 | $-156.0K | $41.8M | ||
| Q2 24 | $6.0M | $70.7M |
| Q1 26 | 44.3% | 36.7% | ||
| Q4 25 | 36.5% | 29.5% | ||
| Q3 25 | 34.9% | 27.1% | ||
| Q2 25 | 39.5% | 23.9% | ||
| Q1 25 | 36.8% | 18.1% | ||
| Q4 24 | 36.0% | 23.1% | ||
| Q3 24 | 38.4% | 29.3% | ||
| Q2 24 | 35.6% | 34.1% |
| Q1 26 | — | 17.3% | ||
| Q4 25 | 13.8% | 9.0% | ||
| Q3 25 | 9.0% | 6.3% | ||
| Q2 25 | 15.4% | 2.6% | ||
| Q1 25 | 14.4% | -5.8% | ||
| Q4 24 | 10.4% | -1.4% | ||
| Q3 24 | 12.6% | 11.9% | ||
| Q2 24 | 13.6% | 17.9% |
| Q1 26 | 10.8% | 15.8% | ||
| Q4 25 | 4.3% | 6.0% | ||
| Q3 25 | 0.3% | 11.1% | ||
| Q2 25 | 3.1% | 1.9% | ||
| Q1 25 | 1.8% | -2.7% | ||
| Q4 24 | -4.3% | 0.4% | ||
| Q3 24 | -0.0% | 12.7% | ||
| Q2 24 | 0.9% | 17.8% |
| Q1 26 | $0.19 | $1.37 | ||
| Q4 25 | $0.10 | $0.43 | ||
| Q3 25 | $0.01 | $0.70 | ||
| Q2 25 | $0.07 | $0.11 | ||
| Q1 25 | $0.04 | $-0.16 | ||
| Q4 24 | $-0.10 | $0.02 | ||
| Q3 24 | $0.00 | $0.80 | ||
| Q2 24 | $0.02 | $1.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $233.2M |
| Total DebtLower is stronger | — | $154.4M |
| Stockholders' EquityBook value | — | — |
| Total Assets | — | $2.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $233.2M | ||
| Q4 25 | $282.0M | $300.0M | ||
| Q3 25 | $201.2M | $336.3M | ||
| Q2 25 | $71.5M | $383.3M | ||
| Q1 25 | $59.2M | $454.9M | ||
| Q4 24 | $110.6M | $491.5M | ||
| Q3 24 | $74.0M | $583.2M | ||
| Q2 24 | $43.8M | $709.0M |
| Q1 26 | — | $154.4M | ||
| Q4 25 | $2.6B | $154.3M | ||
| Q3 25 | $2.6B | $154.1M | ||
| Q2 25 | $2.2B | $153.9M | ||
| Q1 25 | $2.2B | $153.8M | ||
| Q4 24 | $2.4B | $153.6M | ||
| Q3 24 | $2.4B | $153.5M | ||
| Q2 24 | $2.4B | $153.3M |
| Q1 26 | — | — | ||
| Q4 25 | $-70.8M | $2.1B | ||
| Q3 25 | $-109.5M | $2.1B | ||
| Q2 25 | $-112.1M | $2.1B | ||
| Q1 25 | $-131.7M | $2.1B | ||
| Q4 24 | $-109.3M | $2.1B | ||
| Q3 24 | $-93.4M | $2.1B | ||
| Q2 24 | $-57.5M | $2.0B |
| Q1 26 | — | $2.8B | ||
| Q4 25 | $3.7B | $2.8B | ||
| Q3 25 | $3.6B | $2.7B | ||
| Q2 25 | $3.4B | $2.6B | ||
| Q1 25 | $3.4B | $2.6B | ||
| Q4 24 | $3.5B | $2.6B | ||
| Q3 24 | $3.5B | $2.6B | ||
| Q2 24 | $3.5B | $2.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.07× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.07× | ||
| Q1 25 | — | 0.07× | ||
| Q4 24 | — | 0.07× | ||
| Q3 24 | — | 0.07× | ||
| Q2 24 | — | 0.07× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMRX
| Affordable Medicines net | $423.0M | 59% |
| AvKARE net | $166.0M | 23% |
| Specialty net | $133.0M | 18% |
HCC
| Sales | $448.5M | 98% |
| Other revenues | $10.1M | 2% |
